Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1

Journal of Virology

Volumn 86, Issue 15, 2012, Pages 7790-7804

  Gonzalez Hernandez, Marta J ^a,b   Swanson, Michael D ^a,b,d   Contreras Galindo, Rafael ^a   Cookinham, Sarah ^a   King, Steven R ^a   Noel, Richard J ^c   Kaplan, Mark H ^a   Markovitz, David M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENDOGENOUS RETROVIRUS; ENDOGENOUS RETROVIRUS TYPE K; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKEMIA CELL LINE; LONG TERMINAL REPEAT; MUTATIONAL ANALYSIS; NONHUMAN; NP9 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REC GENE; RNA TRANSCRIPTION; VIRUS ACTIVATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS ONCOGENE;

ENDOGENOUS RETROVIRUSES; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, ENV; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; RECOMBINANT PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS ACTIVATION;

HUMAN ENDOGENOUS RETROVIRUS K; HUMAN ENDOGENOUS RETROVIRUSES; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864378847     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07215-11     Document Type: Article

References (139)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Andersson AC, et al. 2002. Developmental expression of HERV-R (ERV3) and HERV-K in human tissue. Virology 297:220-225.
3. Antony JM, Deslauriers AM, Bhat RK, Ellestad KK, Power C. 2010. Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? Biochim. Biophys. Acta.
4. Armbruester V, et al. 2002. A novel gene from the human endogenousretrovirus K expressed in transformed cells. Clin. Cancer Res. 8:1800-1807.
5. Armbruester V, et al. 2002. A novel gene from the human endogenous retrovirus K expressed in transformed cells. Clin. Cancer Res. 8:1800-1807.
6. Armbruester V, et al. 2004. Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J. Virol. 78:10310-10319.
7. Arnold BA, Hepler RW, Keller PM. 1998. One-step fluorescent probe product-enhanced reverse transcriptase assay. Biotechniques 25:98-106.
8. Bannert N, Kurth R. 2004. Retroelements and the human genome: new perspectives on an old relation. Proc. Natl. Acad. Sci. U. S. A. 101(Suppl 2):14572-14579.
9. Barbulescu M, et al. 1999. Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr. Biol. 9:861-868.
10. Berkhout B, Jebbink M, Zsiros J. 1999. Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus. J. Virol. 73:2365-2375.
11. Bieche I, et al. 2003. Placenta-specific INSL4 expression is mediated by a human endogenous retrovirus element. Biol. Reprod. 68:1422-1429.
12. Bieda K, Hoffmann A, Boller K. 2001. Phenotypic heterogeneity of human endogenous retrovirus particles produced by teratocarcinoma cell lines. J. Gen. Virol. 82:591-596.
13. Boese A, et al. 2000. Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. Oncogene 19:4328-4336.
14. Boese A, Sauter M, Mueller-Lantzsch N. 2000. A rev-like NES mediates cytoplasmic localization of HERV-K cORF. FEBS Lett. 468:65-67.
15. Bohan CA, et al. 1992. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr. 2:391-407.
16. Boller K, et al. 2008. Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J. Gen. Virol. 89:567-572.
17. Buonaguro L, Buonaguro FM, Giraldo G, Ensoli B. 1994. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J. Virol. 68: 2677-2682.
18. Buscher K, et al. 2006. Expression of the human endogenous retrovirus-K transmembrane envelope, Rec, and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res. 16:223-234.
19. Caldwell RL, Lane KB, Shepherd VL. 2006. HIV-1 Tat interaction with cyclin T1 represses mannose receptor and the bone morphogenetic protein receptor-2 transcription. Arch. Biochem. Biophys. 449:27-33.
20. Caputo A, Sodroski JG, Haseltine WA. 1990. Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. J. Acquir. Immune Defic. Syndr. 3:372-379.
21. Chu WM, Ballard R, Carpick BW, Williams BR, Schmid CW. 1998. Potential Alu function: regulation of the activity of double-stranded RNA-activated kinase PKR. Mol. Cell. Biol. 18:58-68.
22. Contreras-Galindo R, Almodovar-Camacho S, Gonzalez-Ramirez S, Lorenzo E, Yamamura Y. 2007. Comparative longitudinal studies of HERV-K and HIV-1 RNA titers in HIV-1-infected patients receiving successful versus unsuccessful highly active antiretroviral therapy. AIDS Res. Hum. Retrovir. 23:1083-1086.
23. Contreras-Galindo R, et al. 2006. A new Real-Time-RT-PCR for quantitation of human endogenous retroviruses type K (HERV-K) RNA load in plasma samples: increased HERV-K RNA titers in HIV-1 patients with HAART non-suppressive regimens. J. Virol. Methods 136:51-57.
24. Contreras-Galindo R, et al. 2008. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J. Virol. 82:9329-9336.
25. Contreras-Galindo R, Kaplan MH, Markovitz DM, Lorenzo E, Yamamura Y. 2006. Detection of HERV-K(HML-2) viral RNA in plasma of HIV type 1-infected individuals. AIDS Res. Hum. Retrovir. 22:979-984.
26. Contreras-Galindo R, Lopez P, Velez R, Yamamura Y. 2007. HIV-1 infection increases the expression of human endogenous retroviruses type K (HERV-K) in vitro. AIDS Res. Hum. Retrovir. 23:116-122.
27. Contreras-Galindo RA, et al. 2011. Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals. J. Virol.
28. Dandekar DH, Ganesh KN, Mitra D. 2004. HIV-1 Tat directly binds to NFκB enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res. 32:1270-1278.
29. Das AT, Harwig A, Berkhout B. 2011. The HIV-1 Tat protein has a versatile role in activating viral transcription. J. Virol. 85:9506-9516.
30. Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M. 1996. Activation of transcription factor NF-κB by the Tat protein of human immunodeficiency virus type 1. J. Virol. 70:4427-4437.
31. Denne M, et al. 2007. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J. Virol. 81:5607-5616.
32. Denner J, Phelps RC, Lower J, Lower R, Kurth R. 1995. Antibody response of pregnant women, tumor and AIDS Patients against the human endogenous retrovirus HERV-K. J. Cancer Res. Clin. Oncol. 121:5.
33. Dong QG, et al. 2002. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 21:6510-6519.
34. Dunlap KA, et al. 2006. Endogenous retroviruses regulate periimplantation placental growth and differentiation. Proc. Natl. Acad. Sci. U. S. A. 103:14390-14395.
35. Dunn CA, Medstrand P, Mager DL. 2003. An endogenous retroviral long terminal repeat is the dominant promoter for human beta1,3-galactosyltransferase 5 in the colon. Proc. Natl. Acad. Sci. U. S. A. 100: 12841-12846.
36. Ehlhardt S, et al. 2006. Human endogenous retrovirus HERV-K(HML-2) Rec expression and transcriptional activities in normal and rheumatoid arthritis synovia. J. Rheumatol. 33:16-23.
37. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. 1990. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345:84-86.
38. Ensoli B, et al. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277-287.
39. Evans LH, et al. 2009. Mobilization of endogenous retroviruses in mice after infection with an exogenous retrovirus. J. Virol. 83:2429-2435.
40. Farre D, et al. 2003. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 31: 3651-3653.
41. Flockerzi A, et al. 2008. Expression patterns of transcribed human endogenous retrovirus HERV-K (HML-2) loci in human tissues and the need for a HERV Transcriptome Project. BMC Genomics 9:354. doi: 10.1186/1471-2164-9-354.
42. Frankel AD, Young JA. 1998. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67:1-25.
43. Freimanis G, et al. 2010. A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis. Clin. Exp. Immunol. 160:340-347.
44. Frendo JL, et al. 2003. Direct involvement of HERV-W Env glycoprotein in human trophoblast cell fusion and differentiation. Mol. Cell. Biol. 23:3566-3574.
45. Fuchs NV, et al. 2011. Expression of the human endogenous retrovirus (HERV) group HML-2/HERV-K does not depend on canonical promoter elements but is regulated by transcription factors Sp1 and Sp3. J. Virol. 85:3436-3448.
46. Fujioka S, et al. 2004. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-κB. J. Biol. Chem. 279:27549-27559.
47. Fujioka S, et al. 2003. Inhibition of constitutive NF-κB activity by IκB M suppresses tumorigenesis. Oncogene 22:1365-1370.
48. Galli UM, et al. 2005. Human endogenous retrovirus rec interferes with germ cell development in mice and may cause carcinoma in situ, the predecessor lesion of germ cell tumors. Oncogene 24:3223-3228.
49. Garber ME, et al. 1998. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:3512-3527.
50. Garrison KE, et al. 2007. T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog. 3:e165. doi:10.1371/ journal.ppat.0030165.
51. Gatignol A, Duarte M, Daviet L, Chang YN, Jeang KT. 1996. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr. 5:217-228.
52. Gross H, et al. 2010. The NP9 protein encoded by the human endogenous retrovirus HERV-K (HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2). Int. J. Cancer 129: 1105-1115.
53. Herrmann M, Neidhart M, Gay S, Hagenhofer M, Kalden JR. 1998.Retrovirus-associated rheumatic syndromes. Curr. Opin. Rheumatol. 10:347-354.
54. Herve CA, Lugli EB, Brand A, Griffiths DJ, Venables PJ. 2002. Autoantibodies to human endogenous retrovirus-K are frequently detected in health and disease and react with multiple epitopes. Clin. Exp. Immunol. 128:75-82.
55. Hohenadl C, et al. 1999. Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation. J. Invest. Dermatol. 113:587-594.
56. Howcroft TK, Strebel K, Martin MA, Singer DS. 1993. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 260:1320-1322.
57. Hsiao FC, Lin M, Tai A, Chen G, Huber BT. 2006. Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J. Immunol. 177:2056-2060.
58. Hughes JF, Coffin JM. 2004. Human endogenous retrovirus K solo-LTR formation and insertional polymorphisms: implications for human and viral evolution. Proc. Natl. Acad. Sci. U. S. A. 101:1668-1672.
59. Ishida T, et al. 2008. Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun. 8:15.
60. Jang KL, Collins MK, Latchman DS. 1992. The human immunodeficiency virus tat protein increases the transcription of human Alu repeated sequences by increasing the activity of the cellular transcription factor TFIIIC. J. Acquir. Immune Defic. Syndr. 5:1142-1147.
61. Jeang KT, Xiao H, Rich EA. 1999. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 274:28837-28840.
62. Jern P, Coffin JM. 2008. Effects of retroviruses on host genome function. Annu. Rev. Genet. 42:709-732.
63. Johnston JB, et al. 2001. Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann. Neurol. 50:434-442.
64. Jones KA, Peterlin BM. 1994. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:717-743.
65. Jones RB, et al. 2012. Human endogenous retrovirus K(HML-2) Gagand Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening. Clin. Vaccine Immunol. 19:288-292.
66. Katsumata K, et al. 1999. Cytokine regulation of env gene expression of human endogenous retrovirus-R in human vascular endothelial cells. Clin. Immunol. 93:75-80.
67. Kaufmann S, et al. 2010. Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. J. Gen. Virol. 91:1494-1502.
68. Khan AS, Muller J, Sears JF. 2001. Early detection of endogenous retroviruses in chemically induced mouse cells. Virus Res. 79:39-45.
69. Kinoshita S, et al. 1997. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6:235-244.
70. Kobori M, et al. 2004. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 11: 123-130.
71. Kwun HJ, Han HJ, Lee WJ, Kim HS, Jang KL. 2002. Transactivation of the human endogenous retrovirus K long terminal repeat by herpes simplex virus type 1 immediate-early protein 0. Virus Res. 86:93-100.
72. Laderoute MP, et al. 2007. The replicative activity of human endogenous retrovirus K102 (HERV-K102) with HIV viremia. AIDS 21:2417-2424.
73. Leghmari K, Bennasser Y, Bahraoui E. 2008. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-κB pathways. Eur. J. Cell Biol. 87:947-962.
74. Leghmari K, Contreras X, Moureau C, Bahraoui E. 2008. HIV-1 Tat protein induces TNF-alpha and IL-10 production by human macrophages: differential implication of PKC-βII and -δ isozymes and MAP kinases ERK1/2 and p38. Cell. Immunol. 254:46-55.
75. Lewis N, Williams J, Rekosh D, Hammarskjold ML. 1990. Identification of a cis-acting element in human immunodeficiency virus type 2 (HIV-2) that is responsive to the HIV-1 Rev and human T-cell leukemia virus types I and II rex proteins. J. Virol. 64:1690-1697.
76. Liu J, Perkins ND, Schmid RM, Nabel GJ. 1992. Specific NF-κB subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J. Virol. 66:3883-3887.
77. Löwer R, Löwer J, Kurth R. 1996. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc. Natl. Acad. Sci. U. S. A. 93:5177-5184.
78. Lower R, Tonjes RR, Korbmacher C, Kurth R, Lower J. 1995. Identification of a Rev.-related protein by analysis of spliced transcripts of the human endogenous retroviruses HTDV/HERV-K. J. Virol. 69:141-149.
79. Magin C, Lower R, Lower J. 1999. cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K. J. Virol. 73:9496-9507.
80. Mallet F, et al. 2004. The endogenous retroviral locus ERVWE1 is a bona fide gene involved in hominoid placental physiology. Proc. Natl. Acad. Sci. U. S. A. 101:1731-1736.
81. Mameli G, et al. 2007. Regulation of the syncytin-1 promoter in human astrocytes by multiple sclerosis-related cytokines. Virology 362:120-130.
82. + cell line H9. AIDS Res. Hum. Retrovir. 5:253-255.
83. Mayer J, et al. 1999. An almost-intact human endogenous retrovirus K on human chromosome 7. Nat. Genet. 21:257-258.
84. Medstrand P, Landry JR, Mager DL. 2001. Long terminal repeats are used as alternative promoters for the endothelin B receptor and apolipoprotein C-I genes in humans. J. Biol. Chem. 276:1896-1903.
85. Messeguer X, et al. 2002. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 18: 333-334.
86. Minghetti L, et al. 2004. Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem Res. 29:965-978.
87. Mingyan Y, Xinyong L, De Clercq E. 2009. NF-κB: the inducible factors of HIV-1 transcription and their inhibitors. Mini Rev. Med. Chem. 9:60-69.
88. Molle D, et al. 2007. A real-time view of the TAR:Tat:P-TEFb complex at HIV-1 transcription sites. Retrovirology 4:36.
89. Muster T, et al. 2003. An endogenous retrovirus derived from human melanoma cells. Cancer Res. 63:8735-8741.
90. Nelson PN, et al. 2003. Demystified. Human endogenous retroviruses. Mol. Pathol. 56:11-18.
91. Nguyen KL, Ilano Met al. 2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Revindependent expression. Virology 319:163-175.
92. Noguchi H, et al. 2004. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat. Med. 10:305-309.
93. Ono A, Freed EO. 2001. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U. S. A. 98:13925-13930.
94. Ono M, Kawakami M, Ushikubo H. 1987. Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J. Virol. 61:2059-2062.
95. Ott M, et al. 1997. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275:1481-1485.
96. Padow M, et al. 2000. Analysis of human immunodeficiency virus type 1 containing HERV-K protease. AIDS Res. Hum. Retrovir. 16:1973-1980.
97. Page KA, Landau NR, Littman DR. 1990. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 64:5270-5276.
98. Raney A, Kuo LS, Baugh LL, Foster JL, Garcia JV. 2005. Reconstitution and molecular analysis of an active human immunodeficiency virus type 1 Nef/p21-activated kinase 2 complex. J. Virol. 79:12732-12741.
99. Ratner L, et al. 1987. Complete nucleotide sequences of functional clones of the virus associated with the acquired immunodeficiency syndrome, HTLV-1II/LAV. Haematol Blood Transfus. 31:404-406.
100. Ratner L, et al. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retrovir. 3:57-69.
101. Reiche J, Pauli G, Ellerbrok H. 2010. Differential expression of human endogenous retrovirus K transcripts in primary human melanocytes and melanoma cell lines after UV irradiation. Melanoma Res. 20:435-440.
102. Romani B, Engelbrecht S, Glashoff RH. 2010. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J. Gen. Virol. 91:1-12.
103. Ruda VM, et al. 2004. Tissue specificity of enhancer and promoter activities of a HERV-K (HML-2) LTR. Virus Res. 104:11-16.
104. Ruprecht K, et al. 2008. Human endogenous retrovirus family HERVK(HML-2) RNA transcripts are selectively packaged into retroviral par-ticles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21. J. Virol. 82:10008-10016.
105. Sadaie MR, Benter T, Wong-Staal F. 1988. Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1. Science 239:910-913.
106. Sauter M, et al. 1996. Specificity of antibodies directed against Env protein of human endogenous retroviruses in patients with germ cell tumors. Cancer Res. 56:4362-4365.
107. Sauter M, et al. 1995. Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J. Virol. 69:414-421.
108. Scala G, et al. 1994. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179: 961-971.
109. Schaeffer E, Geleziunas R, Greene WC. 2001. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J. Virol. 75:2993-3000.
110. Schanab O, et al. 2011. Expression of human endogenous retrovirus K is stimulated by ultraviolet radiation in melanoma. Pigment Cell Melanoma Res. 24:656-665.
111. Seifarth W, et al. 1998. Proviral structure, chromosomal location, and expression of HERV-K-T47D, a novel human endogenous retrovirus derived from T47D particles. J. Virol. 72:8384-8391.
112. Sekigawa I, et al. 2010. A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. Clin. Exp. Rheumatol. 28:419-423.
113. Sekigawa I, Ogasawara H, Kaneko H, Hishikawa T, Hashimoto H. 2001. Retroviruses and autoimmunity. Intern. Med. 40:80-86.
114. Serafino A, et al. 2009. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp. Cell Res. 315:849-862.
115. Shi J, Qin X, Zhao L, Wang G, Liu C. 2011. Human immunodeficiency virus type 1 Tat induces B7-H1 expression via ERK/MAPK signaling pathway. Cell. Immunol. 271:280-285.
116. Stevens RW, et al. 1999. Antibody to human endogenous retrovirus peptide in urine of human immunodeficiency virus type 1-positive patients. Clin. Diagn. Lab. Immunol. 6:783-786.
117. Subramanian RP, Wildschutte JH, Russo C, Coffin JM. 2011. Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses. Retrovirology 8:90.
118. Sune C, Garcia-Blanco MA. 1995. Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. J. Virol. 69:6572-6576.
119. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM. 2010. A lectin isolated from bananas is a potent inhibitor of HIV replication. J. Biol. Chem. 285:8646-8655.
120. Tada H, et al. 1990. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc. Natl. Acad. Sci. U. S. A. 87:3479-3483.
121. Tai AK, Luka J, Ablashi D, Huber BT. 2009. HHV-6A infection induces expression of HERV-K18-encoded superantigen. J. Clin. Virol. 46:47-48.
122. Takeda S, Sugimoto K, Otsuki H, Hirochika H. 1998. Transcriptional activation of the tobacco retrotransposon Tto1 by wounding and methyl jasmonate. Plant Mol. Biol. 36:365-376.
123. Tandon R, et al. 2011. Identification of human endogenous retrovirusspecific T cell responses in vertically HIV-1-infected subjects. J. Virol. 85:11526-11531.
124. Ting CN, Rosenberg MP, Snow CM, Samuelson LC, Meisler MH. 1992. Endogenous retroviral sequences are required for tissue-specific expression of a human salivary amylase gene. Genes Dev. 6:1457-1465.
125. Toufaily C, Landry S, Leib-Mosch C, Rassart E, Barbeau B. 2011. Activation of LTRs from different human endogenous retrovirus (HERV) families by the HTLV-1 tax protein and T-cell activators. Viruses 3:2146-2159.
126. Towler EM, et al. 1998. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease? Biochemistry 37:17137-17144.
127. Turcanova VL, Bundgaard B, Hollsberg P. 2009. Human herpesvirus-6B induces expression of the human endogenous retrovirus K18-encoded superantigen. J. Clin. Virol. 46:15-19.
128. Turner G, et al. 2001. Insertional polymorphisms of full-length endogenous retroviruses in humans. Curr. Biol. 11:1531-1535.
129. Vacca A, et al. 1994. Human immunodeficiency virus type-1 tat enhances interleukin-2 promoter activity through synergism with phorbol ester and calcium-mediated activation of the NF-AT cis-regulatory motif. Biochem. Biophys. Res. Commun. 205:467-474.
130. van der Kuyl AC. 2012. HIV infection and HERV expression: a review. Retrovirology 9:6.
131. Villarreal L. 2012. Viruses and host evolution: virus-mediated self identity. Adv. Exp. Med. Biol. 738:185-217.
132. Wang-Johanning F, et al. 2012. Immunotherapeutic potential of antihuman endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J. Natl. Cancer Inst. 104:189-210.
133. Weissman JD, et al. 1998. HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc. Natl. Acad. Sci. U. S. A. 95:11601-11606.
134. Williams RD, Lee BA, Jackson SP, Proudfoot NJ. 1996. Activation domains of transcription factors mediate replication-dependent transcription from a minimal HIV-1 promoter. Nucleic Acids Res. 24:549-557.
135. Yang J, et al. 1999. An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein. Proc. Natl. Acad. Sci. U. S. A. 96:13404-13408.
136. Yang S, et al. 1999. Generation of retroviral vector for clinical studies using transient transfection. Hum. Gene Ther. 10:123-132.
137. Yedavalli VS, Benkirane M, Jeang KT. 2003. Tat and trans-activationresponsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J. Biol. Chem. 278:6404-6410.
138. Yezid H, Konate K, Debaisieux S, Bonhoure A, Beaumelle B. 2009. Mechanism for HIV-1 Tat insertion into the endosome membrane. J. Biol. Chem. 284:22736-22746.
139. Zsiros J, Jebbink MF, Lukashov VV, Voute PA, Berkhout B. 1998. Evolutionary relationships within a subgroup of HERV-K-related human endogenous retroviruses. J. Gen. Virol. 79(Pt 1):61-70.